Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1

Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPN) include BCR-ABL1 and rearranged PDGFR proteins. The latter are products of intra- (e.g. FIP1L1-PDGFRA) or inter-chromosomal (e.g.ETV6-PDGFRB) gene fusions. BCR-ABL1 is associated with chronic myelogenous leukaemia (CML) and...

Descripción completa

Detalles Bibliográficos
Autor principal: Tefferi, Ayalew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2009
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823350/
https://www.ncbi.nlm.nih.gov/pubmed/19175693
http://dx.doi.org/10.1111/j.1582-4934.2008.00559.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823350/
https://www.ncbi.nlm.nih.gov/pubmed/19175693
http://dx.doi.org/10.1111/j.1582-4934.2008.00559.x

Ejemplares similares